Use of a Biomarker in Exposure–Response Analysis to Support Dose Selection for Fingolimod

Fingolimod 0.5 mg q.d. (once daily) has been approved for the treatment of patients with relapsing and remitting forms of multiple sclerosis (RRMS). Fingolimod at two doses (0.5 and 1.25 mg) showed superior effectiveness in the frequency of relapse with little difference between the two dose groups....

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, J-Y, Wang, Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828008/
https://www.ncbi.nlm.nih.gov/pubmed/23965783
http://dx.doi.org/10.1038/psp.2013.44

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828008/
https://www.ncbi.nlm.nih.gov/pubmed/23965783
http://dx.doi.org/10.1038/psp.2013.44

Ejemplares similares